

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Omarigliptin Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-  
stance/Mixture : Pharmaceutical

Recommended restrictions  
on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Innishannon  
County Cork - Ireland

Telephone : 353 214329300

E-mail address of person  
responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated  
exposure, Category 2

H373: May cause damage to organs through pro-  
longed or repeated exposure.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H373 May cause damage to organs through prolonged  
or repeated exposure.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

Precautionary statements : **Prevention:**  
P260 Do not breathe dust.  
**Response:**  
P314 Get medical advice/ attention if you feel unwell.

### Hazardous components which must be listed on the label:

Omarigliptin

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.  
Contact with dust can cause mechanical irritation or drying of the skin.  
May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Omarigliptin	1226781-44-7	STOT RE 2; H373 (Stomach, Blood, Kidney)	>= 10 - < 20

For explanation of abbreviations see section 16.

## SECTION 4: First aid measures

### 4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

---

when the potential for exposure exists (see section 8).

- |                         |   |   |
|-------------------------|---|---|
| If inhaled              | : | If inhaled, remove to fresh air.<br>Get medical attention if symptoms occur.  |
| In case of skin contact | : | Wash with water and soap.<br>Get medical attention if symptoms occur.   |
| In case of eye contact  | : | If in eyes, rinse well with water.<br>Get medical attention if irritation develops and persists.                        |
| If swallowed            | : | If swallowed, DO NOT induce vomiting.<br>Get medical attention if symptoms occur.<br>Rinse mouth thoroughly with water. |

### 4.2 Most important symptoms and effects, both acute and delayed

- |       |   |   |
|-------|---|---|
| Risks | : | Contact with dust can cause mechanical irritation or drying of the skin.<br>Dust contact with the eyes can lead to mechanical irritation.<br><br>May cause damage to organs through prolonged or repeated exposure. |
|-------|---|---|

### 4.3 Indication of any immediate medical attention and special treatment needed

- |           |   |   |
|-----------|---|---|
| Treatment | : | Treat symptomatically and supportively. |
|-----------|---|---|
- 

## SECTION 5: Firefighting measures

### 5.1 Extinguishing media

- |                                |   |  |
|--------------------------------|---|--|
| Suitable extinguishing media   | : | Water spray<br>Alcohol-resistant foam<br>Carbon dioxide (CO <sub>2</sub> )<br>Dry chemical |
| Unsuitable extinguishing media | : | None known.  |

### 5.2 Special hazards arising from the substance or mixture

- |                                       |   |   |
|---------------------------------------|---|---|
| Specific hazards during fire-fighting | : | Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.<br>Exposure to combustion products may be a hazard to health. |
| Hazardous combustion products         | : | Carbon oxides<br>Metal oxides   |

### 5.3 Advice for firefighters

- |                              |   |  |
|------------------------------|---|--|
| Special protective equipment | : | In the event of fire, wear self-contained breathing apparatus. |
|------------------------------|---|--|

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

for firefighters Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

#### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

#### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### SECTION 7: Handling and storage

#### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.  
Local/Total ventilation : Use only with adequate ventilation.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

- Advice on safe handling : Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Avoid prolonged or repeated contact with skin.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.

### 7.2 Conditions for safe storage, including any incompatibilities

- Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.
- Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents

### 7.3 Specific end use(s)

- Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

- dusts non-specific 4 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust)  
Basis: IE OEL
- 10 mg/m<sup>3</sup>  
Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust)  
Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Cellulose	9004-34-6	OELV - 8 hrs (TWA)	10 mg/m <sup>3</sup>	IE OEL
Omarigliptin	1226781-44-7	TWA	10 µg/m <sup>3</sup>	Internal
		Wipe limit	100 µg/100 cm <sup>2</sup>	Internal

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

### 8.2 Exposure controls

#### Engineering measures

Ensure adequate ventilation, especially in confined areas.  
Minimize workplace exposure concentrations.  
Apply measures to prevent dust explosions.  
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).

#### Personal protective equipment

Eye/face protection : Wear the following personal protective equipment:  
Safety goggles  
Equipment should conform to I.S. EN 166

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the glove manufacturer. Wash hands before breaks and at the end of workday.

Skin and body protection : Skin should be washed after contact.

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.  
Equipment should conform to I.S. EN 143

Filter type : Particulates type (P)

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Physical state : tablet

Colour : yellow

Odour : No data available

Odour Threshold : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

---

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Flash point : No data available

Auto-ignition temperature : No data available

Decomposition temperature : No data available

pH : No data available

Viscosity

Viscosity, dynamic : No data available

Viscosity, kinematic : No data available

Solubility(ies)

Water solubility : No data available

Partition coefficient: n-octanol/water : No data available

Vapour pressure : No data available

Density : No data available

Relative vapour density : No data available

Particle characteristics

Particle size : No data available

### 9.2 Other information

Explosives : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Evaporation rate : No data available

Molecular weight : No data available

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

### SECTION 10: Stability and reactivity

#### 10.1 Reactivity

Not classified as a reactivity hazard.

#### 10.2 Chemical stability

Stable under normal conditions.

#### 10.3 Possibility of hazardous reactions

Hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.  
Can react with strong oxidizing agents.

#### 10.4 Conditions to avoid

Conditions to avoid : Heat, flames and sparks.  
Avoid dust formation.

#### 10.5 Incompatible materials

Materials to avoid : Oxidizing agents

#### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

### SECTION 11: Toxicological information

#### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure : Inhalation  
Skin contact  
Ingestion  
Eye contact

##### Acute toxicity

Not classified based on available information.

##### Components:

##### Omarigliptin:

Acute oral toxicity : LD50 (Rat): 750 mg/kg

##### Skin corrosion/irritation

Not classified based on available information.

##### Components:

##### Omarigliptin:

Result : No skin irritation

##### Serious eye damage/eye irritation

Not classified based on available information.



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

---

### Components:

#### **Omarigliptin:**

Species	:	Bovine cornea
Result	:	No eye irritation

### **Respiratory or skin sensitisation**

#### **Skin sensitisation**

Not classified based on available information.

#### **Respiratory sensitisation**

Not classified based on available information.

### Components:

#### **Omarigliptin:**

Test Type	:	Local lymph node assay (LLNA)
Species	:	Mouse
Assessment	:	Does not cause skin sensitisation.
Result	:	negative

### **Germ cell mutagenicity**

Not classified based on available information.

### Components:

#### **Omarigliptin:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES) Result: negative
-----------------------	---	--

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Result: negative

Genotoxicity in vivo	:	Test Type: Mutagenicity (in vivo mammalian bone-marrow cytogenetic test, chromosomal analysis) Species: Rat Application Route: Intraperitoneal injection Result: negative
----------------------	---	--

### **Carcinogenicity**

Not classified based on available information.

### Components:

#### **Omarigliptin:**

Species	:	Rat
Application Route	:	Oral
Exposure time	:	2 Years
	:	20 mg/kg body weight
Result	:	negative

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

Species	:	Mouse
Application Route	:	Oral
Exposure time	:	2 Years
	:	20 mg/kg body weight
Result	:	negative

### Reproductive toxicity

Not classified based on available information.

#### Components:

##### Omarigliptin:

Effects on fertility	:	Test Type: Fertility/early embryonic development Species: Rat Application Route: Oral Fertility: NOAEL: 100 mg/kg body weight Result: negative
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rabbit Developmental Toxicity: NOAEL: > 50 mg/kg body weight Result: No effects on foetal development
	:	Test Type: Embryo-foetal development Species: Rat Application Route: Oral Developmental Toxicity: LOAEL: 100 mg/kg body weight Result: Reduced offspring weight gain, Reduced maternal food consumption, Skeletal malformations Remarks: The effects were seen only at maternally toxic doses.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

#### Components:

##### Omarigliptin:

Exposure routes	:	Ingestion
Target Organs	:	Stomach, Blood, Kidney
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

#### Components:

##### Omarigliptin:

Species	:	Rat
---------	---	-----

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

NOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 90 Days  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 10 mg/kg  
LOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 180 Days  
Target Organs : Blood, Kidney

Species : Dog  
NOAEL : 10 mg/kg  
LOAEL : 75 mg/kg  
Application Route : Oral  
Exposure time : 40 Days  
Target Organs : Stomach

Species : Dog  
NOAEL : 10 mg/kg  
LOAEL : 75 mg/kg  
Application Route : Oral  
Exposure time : 270 Days  
Target Organs : Stomach

Species : Monkey  
NOAEL : 9 mg/kg  
Application Route : Oral  
Exposure time : 90 Days  
Remarks : No significant adverse effects were reported

### Aspiration toxicity

Not classified based on available information.

## 11.2 Information on other hazards

### Endocrine disrupting properties

Not classified based on available information.

### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### Experience with human exposure

### Components:

### Omarigliptin:

Ingestion : Symptoms: Headache, stomach discomfort, Dizziness, Tired-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

ness, Diarrhoea, flu-like symptoms, Back pain, Vomiting, chills

### SECTION 12: Ecological information

#### 12.1 Toxicity

##### Components:

##### **Omarigliptin:**

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202

EC50 (Americamysis): > 100 mg/l  
Exposure time: 96 h  
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 100 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 25 mg/l  
Exposure time: 72 h  
Method: OECD Test Guideline 201

Toxicity to microorganisms : EC50 : > 1,000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

NOEC : 0.1 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209

Toxicity to fish (Chronic toxicity) : NOEC: 11 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 11 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211

#### 12.2 Persistence and degradability

##### Components:

##### **Omarigliptin:**

Biodegradability : Result: Not readily biodegradable.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

---

Biodegradation: 50 %  
Exposure time: 11 d  
Method: OECD Test Guideline 314

### 12.3 Bioaccumulative potential

#### Components:

##### **Omarigliptin:**

Partition coefficient: n- : log Pow: 0.525  
octanol/water

### 12.4 Mobility in soil

#### Components:

##### **Omarigliptin:**

Distribution among environ- : log Koc: 4.01  
mental compartments Method: OECD Test Guideline 106

### 12.5 Results of PBT and vPvB assessment

#### Product:

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

#### Product:

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product	: Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	: Empty containers should be taken to an approved waste handling site for recycling or disposal.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

If not otherwise specified: Dispose of as unused product.

### SECTION 14: Transport information

#### 14.1 UN number or ID number

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.2 UN proper shipping name

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.3 Transport hazard class(es)

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA	:	Not regulated as a dangerous good

#### 14.4 Packing group

ADN	:	Not regulated as a dangerous good
ADR	:	Not regulated as a dangerous good
RID	:	Not regulated as a dangerous good
IMDG	:	Not regulated as a dangerous good
IATA (Cargo)	:	Not regulated as a dangerous good
IATA (Passenger)	:	Not regulated as a dangerous good

#### 14.5 Environmental hazards

Not regulated as a dangerous good

#### 14.6 Special precautions for user

Not applicable

#### 14.7 Maritime transport in bulk according to IMO instruments

Remarks	:	Not applicable for product as supplied.
---------	---	---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

### SECTION 15: Regulatory information

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	: Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	: Not applicable
Regulation (EU) No 2024/590 on substances that deplete the ozone layer	: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast)	: Not applicable
Regulation (EU) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals	: Not applicable
REACH - List of substances subject to authorisation (Annex XIV)	: Not applicable
Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.	Not applicable

#### Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

#### The components of this product are reported in the following inventories:

AICS	: not determined
DSL	: not determined
IECSC	: not determined

#### 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

### SECTION 16: Other information

Other information	: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.
-------------------	--

#### Full text of H-Statements

H373	: May cause damage to organs through prolonged or repeated exposure if swallowed.
------	---

#### Full text of other abbreviations

STOT RE	: Specific target organ toxicity - repeated exposure
IE OEL	: Ireland. List of Chemical Agents and Carcinogens with Occu-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

Occupational Exposure Limit Values - Code of Practice, Schedule 1 and 2

IE OEL / OELV - 8 hrs (TWA) : Occupational exposure limit value (8-hour reference period)

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

STOT RE 2

H373

### Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Omarigliptin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 28.09.2024
3.4	14.04.2025	443746-00022	Date of first issue: 07.01.2016

---

intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN